Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBIT (2020 - 2025)

Historic EBIT for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.1 million.

  • Tango Therapeutics' EBIT rose 14280.07% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 2101.89%. This contributed to the annual value of -$145.6 million for FY2024, which is 2752.14% down from last year.
  • Latest data reveals that Tango Therapeutics reported EBIT of $14.1 million as of Q3 2025, which was up 14280.07% from -$41.0 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EBIT ranged from a high of $14.1 million in Q3 2025 and a low of -$42.5 million during Q1 2025
  • In the last 5 years, Tango Therapeutics' EBIT had a median value of -$29.6 million in 2024 and averaged -$26.2 million.
  • As far as peak fluctuations go, Tango Therapeutics' EBIT tumbled by 96515423.73% in 2021, and later soared by 14280.07% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' EBIT stood at -$22.0 million in 2021, then plummeted by 39.04% to -$30.6 million in 2022, then decreased by 14.55% to -$35.0 million in 2023, then fell by 16.84% to -$40.9 million in 2024, then surged by 134.4% to $14.1 million in 2025.
  • Its EBIT stands at $14.1 million for Q3 2025, versus -$41.0 million for Q2 2025 and -$42.5 million for Q1 2025.